Summary:
CTT is conducting a research study testing the safety and effectiveness of an investigational long-acting insulin when compared to Lantus in adults with Type 1 Diabetes.
Qualified Participants Must:
• Be 18 years of age or older
•
Be diagnosed with Type 1 Diabetes for at least one year
•
Currently be using a short and long acting insulin
•
Have an HbA1c below 9%
•
Additional criteria may apply
Qualified Participants May Receive:
Compensation up to $1,670 will be available for time and travel. You will also receive study-related medication, tests, glucose meter and supplies, and care from a board-certified physician at no cost.